242
Views
7
CrossRef citations to date
0
Altmetric
Review

Advances in potential targeted therapies for Erdheim-Chester disease

, &
Pages 253-260 | Received 05 Dec 2016, Accepted 18 Jan 2017, Published online: 01 Feb 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Giulio Cavalli & Ennio Giulio Favalli. (2019) Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Review of Clinical Immunology 15:12, pages 1313-1322.
Read now
Fréderic Franconieri, Samuel Deshayes, Hubert de Boysson, Salim Trad, Nicolas Martin Silva, Benjamin Terrier, Boris Bienvenu, Françoise Galateau-Sallé, Jean-François Emile, Alison C. Johnson & Achille Aouba. (2018) Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. OncoImmunology 7:8.
Read now
Greta Pacini, Giulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, Guido Pacini, Marina Ferrarini, Claudio Doglioni & Lorenzo Dagna. (2018) The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. OncoImmunology 7:7.
Read now
Alvise Berti, Giulio Cavalli, Barbara Guglielmi, Riccardo Biavasco, Corrado Campochiaro, Alessandro Tomelleri, Roberto Nicoletti, Andrea Panzacchi, Marina Ferrarini & Lorenzo Dagna. (2017) Tocilizumab in patients with multisystem Erdheim–Chester disease. OncoImmunology 6:6.
Read now

Articles from other publishers (3)

Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Cosimo Bruni, Alessandro Tomelleri, Lorenzo Dagna & Marco Matucci-Cerinic. (2021) Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. Frontiers in Immunology 12.
Crossref
Giulio Cavalli & Charles A. Dinarello. (2018) Anakinra Therapy for Non-cancer Inflammatory Diseases. Frontiers in Pharmacology 9.
Crossref
Alessandro Tomelleri, Giulio Cavalli, Giacomo De Luca, Corrado Campochiaro, Teresa D’Aliberti, Moreno Tresoldi & Lorenzo Dagna. (2018) Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease. Frontiers in Immunology 9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.